Gilead Beats $50M Drug Bonus Call In Del. Chancery Ruling
By Jeff Montgomery ( March 15, 2017, 4:47 PM EDT) -- Gilead Sciences Inc. defeated a merger partner's $50 million cancer-drug bonus demand after a Delaware Chancery Court ruled Wednesday that the Calistoga Pharmaceuticals Inc. compound involved never won the broad approval needed to qualify for the post-merger payment....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.